GDNF poses troubling questions for doctors, drug maker. Toxicity, negative outcome raise doubts

No authors listed

Comment

No authors listed. Ann Neurol. 2006 Mar.

. 2006 Mar;59(3):A5-6.

doi: 10.1002/ana.20805.

No abstract available

Comment in

Reply: GDNF poses troubling questions for doctors, drug maker.
Slevin JT, Gerhardt GA, Smith CD, Gash DM, Young AB. Slevin JT, et al. Ann Neurol. 2006 Jun;59(6):989-90. doi: 10.1002/ana.20880. Ann Neurol. 2006. PMID: 16718700 No abstract available.

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. Lang AE, et al. Ann Neurol. 2006 Mar;59(3):459-66. doi: 10.1002/ana.20737. Ann Neurol. 2006. PMID: 16429411 Clinical Trial.